Compare PMCB & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMCB | FRSX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Israel |
| Employees | N/A | 74 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.1M |
| IPO Year | 2001 | 2016 |
| Metric | PMCB | FRSX |
|---|---|---|
| Price | $0.44 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 302.6K | 81.7K |
| Earning Date | 03-17-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.78 |
| 52 Week High | $1.51 | $3.00 |
| Indicator | PMCB | FRSX |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 46.94 |
| Support Level | $0.33 | $1.05 |
| Resistance Level | $0.77 | $1.47 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 63.10 | 39.32 |
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.